Krueger, Annika http://orcid.org/0000-0001-5831-5919
Zaugg, Julian http://orcid.org/0000-0002-4919-1448
Lachner, Nancy
Bialasiewicz, Seweryn http://orcid.org/0000-0001-9474-6943
Lin, Lynlee L http://orcid.org/0000-0003-3100-9668
Gabizon, Sharon http://orcid.org/0000-0003-3765-8589
Sobarun, Priyamvada http://orcid.org/0000-0002-7095-7786
Morrison, Mark http://orcid.org/0000-0001-9257-9133
Soyer, H Peter http://orcid.org/0000-0002-4770-561X
Hugenholtz, Philip http://orcid.org/0000-0001-5386-7925
Frazer, Ian H http://orcid.org/0000-0002-8002-4680
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1071822, APP1059012, APP1181054, APP1111216, APP1137127)
Department of Health | National Health and Medical Research Council (APP1071822, APP1059012, APP1181054, APP1111216, APP1137127)
Article History
Received: 4 August 2021
Revised: 11 January 2022
Accepted: 18 January 2022
First Online: 1 February 2022
Competing interests
: HPS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH, and undertakes regular teledermatological reporting for both companies. HPS is also a Medical Consultant for Canfield Scientific Inc., a Medical Advisor for First Derm and Revenio.